In 2026, U.S. employers are staring down another year of healthcare inflation with fewer tools to absorb it. Drugmakers plan to raise prices on at least 350 branded medications this year, with a median increase of about 4%. At the same time, the three largest pharmacy benefit managers now control nearly 80% of prescriptions filled in the United States, giving them enormous influence over pricing, access, and reimbursement. The result is that many employers are being asked to fund a benefits system they cannot fully see, audit, or predict. For corporate leadership, this is no longer just a benefits issue. It is a financial governance issue, a workforce issue, and increasingly, a business continuity issue.
The Prescription Benefit Is Becoming an Enterprise Risk Problem
For years, rising healthcare costs were treated as a slow-moving pressure that could be managed through annual renewals, modest plan design changes, and cost-sharing adjustments. That approach is no longer enough. Specialty medications, biologics, and other high-cost therapies are now driving a disproportionate share of total pharmacy spending, and even one catastrophic claim can materially disrupt an employer's annual forecast.
This pressure is not only coming from manufacturers' list prices. It is compounded by the internal mechanics of the pharmacy supply chain. Pharmacy benefit managers were originally designed to simplify claims adjudication. Over time, however, consolidation and vertical integration have transformed them into powerful gatekeepers that influence which drugs are covered, where prescriptions are filled, how rebates are structured, and what patients pay at the counter.
That structure creates a serious visibility problem for employers. When pricing is shaped by confidential rebate arrangements, affiliated specialty pharmacy requirements, spread pricing, and opaque network rules, employers are left trying to manage a major corporate expense without a clear line of sight into how their dollars are being used. The Federal Trade Commission's recent reporting on specialty generic markups and excess PBM revenue only deepens concerns that employers may be underwriting profits embedded in a system they cannot fully govern.
The practical consequence is that financial risk has shifted. The vendors and intermediaries operating within the pharmacy ecosystem continue to collect revenue through administrative and contractual mechanisms, while employers absorb rising trends and employees face growing out-of-pocket exposure. As costs continue climbing, many organizations will continue to respond the only way they believe they can: by increasing deductibles, narrowing coverage, or pushing more expenses onto the workforce. That may protect the short-term budget, but it weakens trust and puts employee retention at risk.
The Cost Problem Is Not Just Pricing, It Is Pricing Without Accountability.
There is a tendency in public debate to focus narrowly on manufacturers as solely responsible for high list prices. Drug prices are set by manufacturers, but that does not tell the whole story. In many cases, manufacturers are unable to lower the list price because the system is still built around rebates, formulary placement economics, and access controls that sit between the manufacturer and the patient.
This is especially true in specialty pharmacy. Specialty labeling can function as a control mechanism, routing prescriptions to PBM-affiliated pharmacies and reinforcing a closed ecosystem where one organization may influence pricing, approval, dispensing, and reimbursement. From the employer's perspective, that is a deeply unstable arrangement. It combines concentrated financial risk with limited transparency and weak accountability.
It also creates a false sense of value. Higher spending is often framed as the unavoidable cost of innovation, but there is too little connection between the price of a medication and the value it delivers to the patient. In a functioning market, buyers can assess cost against alternatives, outcomes, and real-world impact. In the current system, that relationship is often obscured by layers of contractual complexity that make rational purchasing nearly impossible.
For executives responsible for enterprise planning, that opacity should be unacceptable. Healthcare may be complicated, but complexity does not excuse a lack of auditability. When a major line item cannot be traced clearly, forecasted reliably, or evaluated against measurable value, it becomes a risk management problem.
What Forward-Looking Employers Are Doing Differently
The organizations best positioned to weather the next phase of healthcare inflation are not waiting for policy reform to solve their budgeting problems. They are rethinking prescription benefits as a supply chain and financial design issue, not just an insurance issue.
They are asking more basic questions. Who is being paid, and for what? Which incentives reward higher spending rather than lower net cost? What percentage of spending is truly tied to clinical value? Where does the employer's fiduciary responsibility begin when plan assets are flowing through multiple opaque intermediaries?
That shift in mindset is leading some employers toward more transparent procurement and pricing structures that restore accountability and predictability.
- Demand auditable pricing: Executives should expect the same financial clarity in pharmacy benefits that they would demand in any other major vendor relationship. That means rejecting models that depend on hidden fees, undefined spread, or opaque rebate retention. Every dollar spent should be attributable, visible, and understandable.
- Separate insurance from predictable specialty purchasing: Traditional insurance is built for the risk of unknown loss, not recurring predictable expenses. When a known category of high-cost medications is folded into a structure designed for broad risk pooling, distortion follows. Employers are increasingly evaluating whether specialty purchasing should be managed through a more deliberate, transparent framework rather than left inside a black box.
- Use fixed, member-first pass-through models to restore predictability: One of the most important advantages of pass-through pricing is not simply lower cost. It is budget stability. A fixed model that aligns incentives around actual acquisition cost, rather than inflated list price and rebate volume, gives employers a clearer basis for forecasting and helps reduce the pressure to shift costs onto employees.
- Evaluate global sourcing pathways responsibly: When domestic pricing becomes detached from any rational benchmark, employers are increasingly examining compliant international sourcing options. In some cases, individuals may choose to obtain medications from English-speaking countries with regulatory frameworks and manufacturing standards aligned with the U.S. FDA regulation. When coordinated through reputable pharmacy partners and clinical advocacy programs, this approach can provide access to the same high-quality medications sold globally while aligning costs more closely to international benchmarks.
The Employers That Adapt First Will Be Better Positioned for What Comes Next
The prescription benefit crisis is not a temporary spike. It is a structural challenge shaped by consolidation, misaligned incentives, and a growing disconnect between price and value. Specialty therapies will continue to expand. Administrative controls will continue to grow. Financial pressure will continue to move downstream unless employers take a more active role in how pharmacy benefits are designed and purchased.
That is why this moment matters for the C-suite. A benefits strategy built on opacity is no longer sustainable in an era of rising drug costs and concentrated specialty risk. Employers that continue to rely on opaque renewals and inherited contracting structures may find themselves financing a system that grows more expensive while offering less control each year.
The better path is one built on transparency, accountability, and clear alignment between cost and value. In 2026, the employers that treat prescription benefits as a strategic enterprise issue, rather than a passive administrative function, will be the ones best equipped to protect both their balance sheets and their workforce.
